Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bosi, E.
Right arrow Articles by Bonifacio, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bosi, E.
Right arrow Articles by Bonifacio, E.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:2464-2471, 2001
© 2001 by the American Diabetes Association, Inc.

Autoantibody Response to Islet Transplantation in Type 1 Diabetes

Emanuele Bosi, Simona Braghi, Paola Maffi, Miriam Scirpoli, Federico Bertuzzi, Guido Pozza, Antonio Secchi, and Ezio Bonifacio

Medicine and Surgery, San Raffaele Hospital Scientific Institute, Milan, Italy; the University of Milan, Milan, Italy; and the University San Raffaele Vita-Salute, Milan, Italy

Islet allotransplantation into patients with autoimmune type 1 diabetes represents a reexposure to autoantigen. Here, measurement of antibodies to GAD and IA-2 autoantigens before and after islet transplantation in 36 patients (33 receiving islet plus kidney grafts with cyclosporin and steroid-based immunosuppression, and 3 receiving solitary islet transplants with mycophenolate but cyclosporin-free immunosuppression) demonstrated marked rises in GAD antibodies within 7 days posttransplantation in 5 patients (3 receiving islet after kidney transplants, and 2 receiving solitary islet transplants) and within 30 days in the third patient receiving solitary islet transplantation. GAD antibodies were of the IgG1 subclass, against major autoantigenic epitopes, and in cases of islet after kidney transplants, the responses were short-lived and not accompanied by HLA antibodies. Two of these patients had subsequent marked rises of IA-2 antibodies, and an additional patient had a marked rise in IgM-GAD antibodies 3 years after transplantation. Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in these patients. These data are consistent with a reactivation of autoimmunity that may be dependent on immunosuppression therapy and is associated with impaired graft function.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. Rickels, M. Kamoun, J. Kearns, J. F. Markmann, and A. Naji
Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on {beta}-Cell Secretory Capacity
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2410 - 2414.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Bertuzzi and C. Ricordi
Prediction of Clinical Outcome in Islet Allotransplantation
Diabetes Care, February 1, 2007; 30(2): 410 - 417.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
T. M. Kupfer, M. L. Crawford, K. Pham, and R. G. Gill
MHC-Mismatched Islet Allografts Are Vulnerable to Autoimmune Recognition In Vivo
J. Immunol., August 15, 2005; 175(4): 2309 - 2316.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. L. Larsen
Pancreas Transplantation: Indications and Consequences
Endocr. Rev., December 1, 2004; 25(6): 919 - 946.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. S. Eisenbarth and P. A. Gottlieb
Autoimmune Polyendocrine Syndromes
N. Engl. J. Med., May 13, 2004; 350(20): 2068 - 2079.
[Full Text] [PDF]

Home page
 NEJMHome page
R. P. Robertson
Islet Transplantation as a Treatment for Diabetes -- A Work in Progress
N. Engl. J. Med., February 12, 2004; 350(7): 694 - 705.
[Full Text] [PDF]

Home page
 DiabetesHome page
P. Achenbach, K. Warncke, J. Reiter, H. E. Naserke, A. J.K. Williams, P. J. Bingley, E. Bonifacio, and A.-G. Ziegler
Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Diabetes, February 1, 2004; 53(2): 384 - 392.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al.
C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001
Diabetes, January 1, 2004; 53(1): 250 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Schatz, E. A.M. Gale, and M. A. Atkinson
Why Can't We Prevent Type 1 Diabetes?: Maybe it's time to try a different combination
Diabetes Care, December 1, 2003; 26(12): 3326 - 3328.
[Full Text] [PDF]

Home page
 Clin. DiabetesHome page
W. E. Winter, N. Harris, and D. Schatz
Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes
Clin. Diabetes, October 1, 2002; 20(4): 183 - 191.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. A. Ryan, J. R.T. Lakey, B. W. Paty, S. Imes, G. S. Korbutt, N. M. Kneteman, D. Bigam, R. V. Rajotte, and A.M. J. Shapiro
Successful Islet Transplantation: Continued Insulin Reserve Provides Long-Term Glycemic Control
Diabetes, July 1, 2002; 51(7): 2148 - 2157.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.